Dr. Elhamy D. Eskander, MD

Dr. Eskander practices at Frederick Health Hospital in Frederick, Maryland, part of Frederick Health.

Dr. Eskander's NPI, 1528050473, was assigned on August 17, 2005. Dr. Eskander holds Maryland license D48184.

Dr. Eskander's primary practice is Frederick Health Hospital, at 400 West Seventh St, Frederick, MD 21701 in Frederick County. The practice phone is (240) 566-3300.

Dr. Eskander's primary practice is Frederick Health Hospital in Frederick, Maryland, part of Frederick Health. The medical group on file is Frederick Health Medical Group. Dmand AI also links Dr. Eskander to 2 more group practices and clinics and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Eskander practices, 3 sites in all. Vendor and product names are available with a free account.

Medical oncology is Dr. Eskander's primary specialty in the NPI Registry, under taxonomy code 207RX0202X. Dr. Eskander is licensed in Maryland.

CMS data shows 87,500 Medicare services from Dr. Eskander across 47 procedure codes in 2024, for 899 Medicare patients. Medicare paid $1,252,198 for them.

CMS counts 899 Medicare patients who saw Dr. Eskander in 2024. The largest group is 75 to 84, with 353 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 9% are also on Medicaid. Their average risk score is 1.90, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Eskander's median patient age at 65, with 60% women.

In 2024, Dr. Eskander wrote 706 Medicare Part D claims for 146 patients. 66% of them were for generic drugs. CMS names the drug for 586 of them, across 17 drugs with 11 or more claims each, at $1,832,324 in total drug cost. In 2023, CMS named 526 claims across 19 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 83 out of 100 for Dr. Eskander for performance year 2024, reported as part of a group. Dr. Eskander accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Eskander as offering telehealth.

Dmand AI links Dr. Eskander to 9 clinical trials, 6 of them phase 2 studies. 1 is still active or recruiting. Conditions studied include Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung and Small Cell Lung Carcinoma. SWOG Cancer Research Network sponsors the most, 5.

CMS Open Payments shows 365 general payments to Dr. Eskander from 52 drug and device companies from 2016 to 2025. Food and beverage make up the largest share, 92% of the total. Bristol-Myers Squibb Company paid the most, $1,460. It also lists 1 research payment totaling $190 in 2018.